PAM50 and Beyond: When Will Tissue Transcriptomics Guide Clinical Decision-making?

Haywood, Samuel C; Gupta, Shilpa; Heemers, Hannelore V

Haywood, Samuel C; Gupta, Shilpa; Heemers, Hannelore V.

Afiliação

Haywood SC; Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Gupta S; Department of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Heemers HV; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Electronic address: heemerh@ccf.org.

Eur Urol Focus ; 8(4): 916-918, 2022 07.

Article em En | MEDLINE | ID: mdl-36031559

ABSTRACT

ABSTRACT

Emerging transcriptomics-based classifiers show promise as biomarkers to guide clinical decision-making in prostate cancer, but require further research, optimization, and validation.

Assuntos

Neoplasias da Próstata; Transcriptoma; Biomarcadores Tumorais/genética; Tomada de Decisão Clínica; Humanos; Masculino; Prognóstico; Neoplasias da Próstata/genética; Transcriptoma/genética

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Transcriptoma Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google